Indapamid AL

Quick links to important sections

Indapamid AL

Treatment option: Hypertension

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Indapamid AL

Property Description
Active ingredient Indapamide
Form Oral Tablet (film-coated)
Pharmacological Class Thiazide-like Diuretic
Common Use High Blood Pressure (Hypertension)
Origin Synthetic Small Molecule

Indapamid AL is a prescription medicine containing the single active ingredient called Indapamide. It is chemically classified as a thiazide-like diuretic, a pharmacological group often referred to as a “water pill.” The drug is supplied as an oral tablet, a formulation clinically recognized for its reliable administration route. The active substance, Indapamide, is a synthetic small molecule.

The substance is included in the List of Essential Medicines, recognizing its importance in treating cardiovascular conditions globally. This inclusion indicates that the medication is considered one of the safest and most effective needed in a basic health system.


What is the General Purpose of Indapamid AL?

The general purpose of Indapamid AL is to help the body eliminate excess fluid and salt to promote cardiovascular health. It achieves this by acting directly on the kidneys to increase the removal of sodium and water through urine.

This action of decreasing the overall fluid volume circulating in the body makes Indapamid AL useful in two primary therapeutic areas: helping to manage chronic high blood pressure (hypertension) and relieving swelling (edema), which is the buildup of fluid in the tissues. Its function is to provide long-term support for fluid balance, easing the burden on the heart and blood vessels.

Regulatory References

  1. Thiazide-like diuretic
  2. water pill
  3. sodium
  4. water

What side effects are possible with Indapamid AL?

Possible side effects and safety information

The safety profile of Indapamid AL, containing Indapamide, is officially structured around adverse reactions categorized by frequency and the organ systems affected, as established in regulatory documents such as the EMA SmPC and FDA labeling.

Official Adverse Reactions and Frequency

The most frequently classified reactions fall under Metabolism and Nutrition Disorders, with Hypokalaemia (low potassium levels) being a common and clinically significant risk. Other reactions classified as Common include effects on the Nervous System such as headache, dizziness, and asthenia (weakness). Less frequent adverse reactions, classified as Rare, include the onset of gout and pancreatitis.

System-Organ Class Common Adverse Reactions (Examples) Serious Adverse Reactions (Documented)
Metabolic/Nutrition Hypokalaemia, Hyponatraemia Severe electrolyte imbalances (life-threatening)
Nervous System Headache, Dizziness, Asthenia Hepatic Encephalopathy (Liver/CNS)
Eye Disorders Acute Angle-Closure Glaucoma
Skin/Subcutaneous Rash, Photosensitivity Severe dermatological reactions (SJS/TEN)

Regulatory Safety Constraints

The official label documents specific restrictions and considerations. The medication is contraindicated in patients with severe hepatic impairment, severe renal failure (creatinine clearance below 30 ml/min), and pre-existing severe hypokalaemia. For the Paediatric Population, use is not recommended as safety and efficacy have not been established. Furthermore, the risk of acute angle-closure glaucoma is documented as a safety pattern that can occur within hours to weeks of treatment initiation.

This regulatory summary delineates the full spectrum of potential safety outcomes, from frequently reported systemic effects to rare, serious events, providing a neutral description of the drug’s risk characteristics as defined by government health authorities.

Overdose and Emergency Response

The official regulatory profile for Indapamid AL overdose is defined by the profound consequences of exaggerated diuretic action, necessitating immediate medical intervention. Documented clinical manifestations primarily involve severe fluid and electrolyte disturbances, notably Hypovolaemia, Hyponatraemia (low sodium), and critical Hypokalaemia (low potassium).

Clinical signs listed in regulatory labeling include Profound Hypotension (low blood pressure), Vomiting, Dizziness, Weakness, Sleepiness, and Mental Confusion.

The official profile warns of potentially life-threatening outcomes, including Acute Renal Failure due to severe fluid depletion, and Severe Cardiac Arrhythmias, specifically Torsade de pointes, which is associated with Hypokalaemia. Patients with pre-existing hepatic impairment are noted as having a risk of Hepatic Encephalopathy.

In cases of suspected overdose, regulatory documents mandate that the user seek immediate medical attention or contact emergency services immediately. No specific antidote is known for Indapamide; management is exclusively supportive and symptomatic, requiring professional oversight for the restoration of fluid and electrolyte balance and close clinical monitoring, including ECG monitoring.

Therapeutic Uses of Indapamid AL

A medication that supports cardiovascular health in two key domains. It is commonly used to help with both chronic high blood pressure and symptoms related to fluid retention.


Managing Chronic High Blood Pressure

This medication is generally considered relevant for the long-term management of high blood pressure, a condition characterized by heightened physiological activity that creates noticeable physiological strain on the vascular system. Its primary benefit assists with maintaining functional stability and supports the prevention of target organ damage. This application contributes to easing the overall symptom burden. It is considered relevant in scenarios involving specific patient populations, such as older adults and individuals with co-existing conditions.

“This medication is commonly used to help with both chronic high blood pressure and symptoms related to fluid retention.”


Relieving Systemic Fluid Overload and Swelling

Indapamid AL is applied across therapeutic domains where additional symptomatic support is needed for conditions presenting with systemic or localized discomfort. It is used for managing symptom clusters related to systemic imbalance, specifically edema or swelling caused by the retention of excess fluid. This supportive relief supports patients during episodes of heightened discomfort, and is relevant for easing the symptoms related to physical discomfort caused by fluid pooling in tissues, in contexts involving heightened systemic burden.

Quick Fact: Relief for Edema It is applied in addressing physical symptoms of fluid retention, and may assist with managing symptoms related to fluid pooling when edema is a primary manifestation.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Indapamid AL eligibility is strictly defined by regulatory documents, establishing clear boundaries for who can and cannot use the medicine. The official prescribing information classifies non-eligibility primarily based on organ function status and electrolyte imbalance severity.

Eligibility Map Summary

Eligibility Status Populations and Conditions
Contraindicated (Must Not Use) Severe Renal Failure or Severe Liver Function Impairment, including Hepatic Encephalopathy. Also, Severe Hypokalaemia (low potassium) and known hypersensitivity to Indapamide or any sulfonamide-derived drug.
Not Recommended/Not Established Children and Adolescents (le 18 years) as safety and efficacy have not been established. Pregnant and Breastfeeding women.
Conditional Use (Requires Caution) Older Adults (requires monitoring of renal function and potassium). Patients with Mild or Moderate Hepatic Impairment. Individuals with Diabetes Mellitus, Gout, or Hyperuricemia (requires specific monitoring).

The medicine is generally approved for use in adults for its labeled indications, provided they do not meet any contraindicated criteria. Use in the pediatric population is restricted by a lack of established clinical data, as mandated by official prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Indapamid AL based on pharmacodynamic risk and effects on drug clearance.

Documented High-Risk Combinations

Substance Officially Documented Restriction
Lithium Not Recommended. Indapamide reduces Lithium's renal clearance, leading to a high risk of increased plasma concentrations and toxicity.
Torsades de pointes Agents Inadvisable Combination. Increased risk of ventricular arrhythmia due to additive effects, including Indapamide-induced hypokalaemia.

Other Clinically Significant Interactions

Co-administration with Non-Steroidal Anti-inflammatory Drugs (NSAIDs) may cause a reduced blood pressure-lowering effect and carries a risk of acute renal failure, especially in volume-depleted patients. The use of Hypokalaemia-Inducing Agents (e.g., systemic corticosteroids, stimulant laxatives) increases the likelihood of severe hypokalaemia due to additive effects. Furthermore, Indapamide's effect on electrolytes may predispose the patient to the toxic effects of Cardiac Glycosides (Digitalis preparations).

Administration Timing and Special Considerations

Regulatory strategy recommends stopping Indapamide three days prior to initiating an ACE Inhibitor to mitigate the risk of severe hypotension and acute renal failure. Severe electrolyte imbalances, such as hyponatraemia and hypokalaemia, have been reported to be particularly relevant in the elderly female population.

Alcohol consumption may also increase the risk of dizziness.

Mechanism of Action

Dual Mechanism: Fluid Volume and Vascular Resistance

The action of Indapamide involves a dual mechanism that influences two distinct systems: the renal Na^+/ Cl^- reabsorption pathway and the arterial vascular tone. This influence leads to a reduction in plasma fluid volume and simultaneously causes a decrease in vascular smooth muscle tone. This action alters the physiological processes governing extracellular fluid volume and peripheral vascular resistance.

Inhibition of Renal Salt and Water Reabsorption

The drug's primary action is the inhibition of the Sodium-Chloride Cotransporter (NCC) in the kidney's distal convoluted tubule. By blocking the NCC, Indapamide prevents the reabsorption of sodium ( Na^+) and water back into the bloodstream, modifying an early molecular step that influences fluid retention and elimination. This mechanism leads to a reduction of plasma and extracellular fluid volume.

Direct Arterial Smooth Muscle Modulation

Indapamide also engages a separate, non-diuretic mechanism by modulating the smooth muscle cells of the arterial walls, independent of volume changes. This action involves interference with calcium ion movement across the cell membrane. This mechanism results in the relaxation and widening of blood vessels (vasodilation), which reduces the resistance within the circulatory system.

Dosage and Administration Information

How to Use Indapamid AL

Indapamid AL, which contains the active ingredient Indapamide, is administered exclusively through the oral route as a solid tablet form. Official instructions govern the standardized approach to its intake, ensuring consistency with labeling guidelines.


Official Administration Guidelines

Property Description
Route of Administration Oral (tablet form)
Standard Frequency Once daily
Timing Specifics The tablet is directed to be taken in the morning.
Food Intake The tablet may be taken with or without food.
Tablet Handling The tablet must be swallowed whole with water. Modified-Release (MR/SR) forms should not be crushed, chewed, or broken.

Official Dosing and Use Patterns

Dosage schedules are dependent on the treated condition, and adjustment intervals are prescribed by established protocols.

Indication Starting Dose Maximum Daily Dose
Hypertension 1.25 mg once daily 5 mg once daily
Edema 2.5 mg once daily 5 mg once daily

The overall course of therapy is established for long-term management of chronic conditions. Dose adjustments for hypertension are typically separated by a minimum of four weeks.

If a dose is missed, the next dose should be taken at the usual time the following day, and a double dose must not be taken to compensate. The use of this medicine is not recommended in children and adolescents due to a lack of data.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Indapamid AL

This section describes the types of research that have been conducted with Indapamid AL. It aims to present what the studies explored, what findings were observed, and what questions still remain unanswered, using language that avoids clinical advice or certainty about individual outcomes. Findings describe group patterns, not personal outcomes.


Evidence for use in High Blood Pressure (Hypertension)

Research exploring Indapamid AL for high blood pressure was conducted during periods of increased symptom activity and primarily involved randomized controlled trials (RCTs). These studies included adults whose high blood pressure was characterized by conditions where symptoms may vary in intensity. The trials monitored physiological strain or stress by measuring blood pressure over defined time intervals.

What the studies reported is that research highlights changes measured during the study period, specifically that outcomes related to systemic or functional imbalance were observed in some study populations. Research describes patterns observed in measured blood pressure between the group assigned to Indapamid AL and the control groups. The long-term effects on outcomes reflecting daily functioning or activity level are not fully established.


Evidence for use in Fluid Retention (Oedema) Associated with Heart Conditions

Indapamid AL was also studied for outcomes related to fluid retention, which is a condition involving periods of heightened symptoms associated with heart conditions. Studies monitored patient-reported outcomes describing perceived discomfort over short-term observation windows. Studies report how symptoms evolved in the observed populations, with findings indicating patterns related to the monitored physiological strain or stress.

Data are still emerging in this area, and the evidence quality varies across studies. Follow-up durations were limited, meaning there is limited information for long-term outcomes related to fluid retention.


What is Still Uncertain About Indapamid AL

The research provides context but not individual predictions, and evidence highlights what is known—and what is still uncertain. Long-term effects on outcomes reflecting daily functioning or activity level are not fully established because follow-up durations were limited. Comparative evidence is lacking for certain conditions, and data for certain groups (such as children and adolescents) remain insufficient. Findings were mixed across some research, and evidence quality varies across studies, meaning certainty remains low in certain areas.

Frequently Asked Questions (FAQ)

Common questions about Indapamid AL (FAQ)


Q: What is the difference between Indapamid AL and other blood pressure pills?

A: Indapamid AL is classified as a thiazide-like diuretic. Official product information describes that it has a unique dual action compared to some other medicines. This action includes both a diuretic effect (increasing salt and water excretion in the kidneys) and a direct effect that relaxes and widens blood vessels (vasodilation).

Q: How quickly should I expect Indapamid AL to start working?

A: According to the official product information, the initial effect that increases urination may be noticeable within the first few hours of taking the dose. The full anti-hypertensive (blood pressure lowering) effect generally begins to take place within the first one to two weeks of consistent treatment.

Q: Is it common to feel tired when first starting Indapamid AL?

A: Yes, official safety documents list both asthenia (weakness) and fatigue as common adverse reactions. These effects are typically described as mild and transient. If these or other effects persist, it is important to consult a healthcare provider.

Q: What are the most common reasons a doctor might prescribe Indapamid AL?

A: The medicine is officially indicated for two main therapeutic uses, according to regulatory documents. These are the treatment of essential hypertension (high blood pressure) and addressing fluid retention (edema) associated with heart conditions.

Q: Is there a certain time of day that Indapamid AL is usually recommended to be taken?

A: Official guidance recommends taking the tablet once daily in the morning. This specific timing is generally suggested to ensure the diuretic effect (increased need to urinate) occurs during the waking hours and does not interrupt sleep.

Q: Do older adults react differently to Indapamid AL compared to younger patients?

A: Regulatory documents indicate that specific caution is advised for older adults. Older patients require specific monitoring of their renal function and potassium levels, as they may be at a higher risk for severe electrolyte imbalances.

Q: What does it mean that Indapamid AL is used for 'essential hypertension'?

A: The term essential hypertension is used in official documentation to describe the most common form of high blood pressure. This is a condition where the elevated blood pressure has no identifiable underlying medical cause.

Q: What is the typical time frame for reaching the maximum blood pressure lowering effect?

A: The maximum therapeutic effect of Indapamid AL on lowering blood pressure is progressive. Official sources indicate that this full effect is typically reached after 3 to 4 months of consistent treatment.

Q: Can Indapamid AL affect liver enzyme levels shown in blood tests?

A: The drug is contraindicated in severe liver function impairment and can, in rare cases, lead to serious adverse reactions like Hepatic Encephalopathy. Official information indicates that monitoring of liver enzymes may be part of the care plan during treatment.

Q: Is a headache a common side effect reported by users of Indapamid AL?

A: Yes, headache is officially listed as a common adverse reaction. This side effect is typically included in the official classification for nervous system disorders.

Q: What is the general recommendation if a person experiences a rash while on Indapamid AL?

A: A rash is a documented common side effect. Because the drug is associated with rare, severe skin reactions, official documentation states that any sign of a severe skin reaction warrants seeking prompt medical evaluation.

Q: Does Indapamid AL only affect blood pressure, or other conditions too?

A: Regulatory documents describe that Indapamid AL can affect other bodily systems beyond blood pressure. For example, it can alter levels of potassium and sodium, and may increase uric acid and blood glucose levels, which may require monitoring.

Q: Can Indapamid AL affect my blood sugar levels?

A: Yes. Official warnings state that thiazide-related diuretics, including Indapamid AL, may cause or worsen hyperglycemia (high blood sugar). For this reason, special monitoring is required for patients who have diabetes mellitus.

Q: Is Indapamid AL known to cause muscle cramps?

A: Yes, muscle cramps or spasms are officially listed as a common potential side effect. This effect is often linked to the drug’s potential to cause an imbalance in electrolytes, specifically hypokalaemia (low potassium levels).

Q: Can Indapamid AL cause any changes to my vision?

A: Official product information lists effects on vision. The most serious, though rare, is a sudden decrease in vision or eye pain due to Acute Angle-Closure Glaucoma. Other adverse effects like general visual impairment or blurred vision are also documented.

Q: Can taking Indapamid AL affect sleep patterns?

A: Official documents list potential nervous system effects such as vertigo and headache. Additionally, because the drug increases urination, increased night-time bathroom visits may occur, which could indirectly affect sleep patterns.

Q: Does Indapamid AL carry a 'Black Box' warning in the US or similar official caution elsewhere?

A: The drug is not listed with a 'Black Box Warning' (the most severe FDA warning) in the US. However, regulatory documents across regions contain multiple severe warnings and contraindications, including risks of severe electrolyte imbalance and Acute Angle-Closure Glaucoma.

Q: What are the signs that Indapamid AL might be causing too much fluid loss?

A: Signs of excessive fluid or electrolyte loss are documented as potential risks related to the diuretic effect. These symptoms can include dry mouth, unusual tiredness or weakness, increased thirst, headache, or muscle issues like cramps.

Q: Is there a link between Indapamid AL and cholesterol levels?

A: Official warnings note that thiazide-related drugs may cause increases in serum triglyceride and cholesterol levels in some patients. Regulatory documents indicate that monitoring of lipid levels may be part of the care plan during treatment.

Q: Can a small amount of alcohol interact with Indapamid AL?

A: Official information states that alcohol consumption may increase the effects of the anti-hypertensive and diuretic agents. This can lead to a greater risk of orthostatic hypotension (dizziness when standing up) or general dizziness.

Q: Are there specific food restrictions to be aware of when taking Indapamid AL?

A: While the tablet can be taken with or without food, the label emphasizes the risk of hypokalaemia (low potassium). Official documentation notes that diet and salt intake are factors that may influence blood pressure management.

Q: What is the general difference between Indapamid AL and a pure thiazide diuretic?

A: Indapamid AL is classified as a thiazide-like drug. The key difference described in regulatory documents is that it maintains a direct effect on the blood vessel walls (vasodilation) in addition to its diuretic action, whereas pure thiazide diuretics may have less pronounced vascular effects.

Q: Do studies suggest any potential long-term benefits of using Indapamid AL?

A: Yes, research described in official documents indicates that Indapamid AL provides sustained blood pressure control. The drug has also been associated with specific cardiovascular benefits, such as a reduced rate of stroke in high-risk patients.

Q: Why is Indapamid AL sometimes described as an 'anti-hypertensive'?

A: Indapamid AL is officially classified as an anti-hypertensive agent because its main indicated purpose is the treatment of essential hypertension (high blood pressure).

Q: Can Indapamid AL affect laboratory test results for athletes?

A: Yes. Indapamide is on the World Anti-Doping Agency (WADA) Prohibited List as a prohibited diuretic and masking agent. Athletes must be aware that its use may lead to a positive result in doping tests.

Q: What is the meaning of the 'AL' suffix in the drug name Indapamid AL?

A: The 'AL' suffix is a commercial brand identifier used by the specific pharmaceutical company that markets this version of indapamide. It is a product code and does not denote a chemical class or a mechanism of action.

Q: Is Indapamid AL available in different strengths, and why?

A: Yes, it is available in different strengths, such as immediate-release tablets of 1.25 mg and 2.5 mg or prolonged-release tablets of 1.5 mg. This range allows for titration to the lowest effective dose, as higher doses may increase side effects without significantly improving efficacy.

Q: Can Indapamid AL cause stomach upset or nausea?

A: Yes, official safety documents state that gastrointestinal effects, including nausea and vomiting, are officially documented as uncommon side effects.

Q: What is the most serious, but rare, side effect officially associated with Indapamid AL?

A: Documented rare, life-threatening side effects include Acute Angle-Closure Glaucoma (a sudden eye condition), severe skin reactions like Stevens-Johnson Syndrome (SJS), and Hepatic Encephalopathy (severe liver/brain dysfunction). Official documentation states that any sign of these rare, severe events warrants seeking prompt medical evaluation.

Q: Is it possible to develop a tolerance to the effects of Indapamid AL?

A: Official clinical trial results state that the blood pressure lowering effect of Indapamid AL is sustained during long-term treatment. This indicates that tolerance (a lessening of effect over time) is not typically observed.

Q: Is Indapamid AL considered a first-line treatment for hypertension in official guidelines?

A: Yes. Indapamid AL, as a thiazide-like diuretic, is recommended as one of the preferred first-line agents for the management of high blood pressure in major international clinical guidelines.

How should Indapamid AL be stored and disposed of?

Official Storage Requirements

Indapamide tablets must be stored according to regulatory guidelines to maintain stability. The product requires storage at Controlled Room Temperature, typically below 25°C (77°F), and must be protected from excess heat and moisture.

Storage Constraint Requirement
Temperature Store below 25 C (Do not freeze)
Container Keep in the original container, tightly closed.
Environment Protect from excess moisture (Do not store in the bathroom).
Safety Keep out of the sight and reach of children.

Disposal of Unused Medicine

Disposal must comply with environmental and local regulations. Unused or expired Indapamide must not be thrown away via wastewater, such as flushing down a toilet, or household trash. Patients are instructed to consult their pharmacist or local waste management authority for appropriate disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Indapamid AL found in:

A-Z Index: